Kahr-Medical Ltd. (IL)

https://www.kahrbio.com

KAHR is developing the next generation of immuno-oncology drug candidates for the treatment of multiple types of cancer. The Company’s lead product candidate, DSP107, is a first-in-class CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses and activates an effective, local response of both innate and adaptive immunity. KAHR’s technology platform is based on multi-functional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response, while recruiting the adaptive immune system to bind and selectively kill the cancer cells. *

	Start	2020-09-01 existent
	Industry	immune-recruitment cancer drug
	Industry 2	DSP107 CD47x41BB targeting fusion protein (Kahr-Medical)
	Person	Pereg, Yaron (Kahr-Medical 202106 CEO)

	Region	Jerusalem
	Country	Israel
	Street	1 Kiryat Hadassah JBP Bldg., POB 9779
	City	9109701 Jerusalem
	Tel	+972-73-7969196
		Address record changed: 2021-06-19

Basic data	Employees	n. a.

		* Document for »About Section«: Kahr-Medical Ltd.. (6/16/21). "Press Release: Kahr Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline".

		Record changed: 2023-07-10

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Kahr-Medical Ltd. (IL)

[1] Kahr-Medical Ltd.. (6/16/21). "Press Release: Kahr Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]